So Cathie Wood is doing what she does best right now - hunting for deals while the market's distracted elsewhere. Her Ark funds are having a rough stretch, but that's not stopping her from making moves. I've been watching cathie wood buys lately, and honestly, the pattern is interesting.

On Tuesday, she loaded up on three names that caught my eye: Guardant Health, Oklo, and CRISPR Therapeutics. Not exactly household names, but each tells a story about where she thinks the real opportunities are hiding.

Let's start with Guardant Health. This one's actually been a bright spot in her portfolio - up 34% this year while most things are struggling. The company's liquid and tissue oncology tests are generating real revenue already. They're running over 400,000 tests annually now, each one pulling in around $2,500 with solid margins. The math works: that's real business, not speculation. They're targeting profitability by 2028 and expect revenue to hit $2 billion. Sure, they're years away from consistent earnings, but the Guardant360 platform has Medicare coverage for advanced tumors. That's credibility.

Then there's Oklo, which is the wild card here. This advanced fission and nuclear recycling play just went public last year through a SPAC merger. Sam Altman chairs it - yes, the OpenAI guy - which tells you something about the backing. The company recently nailed its first full fuel recycling demonstration, but the stock barely moved on the news. That's exactly the kind of disconnect cathie wood buys into. It's down about 16% this year, trading where it was before the announcement. First quarterly earnings as a public company should be the real catalyst.

CRISPR Therapeutics is where Wood's conviction really shows. She's been betting on gene-editing for years, and CRISPR just got its first FDA approval last year with Casgevy for sickle cell disease and beta-thalassemia. Down 10% this year, but that's the entry point she's looking for. The approval validates the entire platform - it's not just one treatment, it's proof the technology works. More applications are coming.

What's interesting about cathie wood buys right now is the theme running through all three. None of these are cheap or proven cash cows. Guardant's still years from consistent profits. Oklo hasn't reported earnings yet. CRISPR just got its first approval. But each one has something real - clinical data, commercial traction, or technological validation - that justifies the risk. That's the Ark playbook: find the disruptors everyone's sleeping on because they're not profitable yet.

The broader point? When cathie wood buys stocks like these, she's betting on transformation, not current valuations. Whether that bet pays off depends on execution, but the logic is sound. These aren't lottery tickets - they're companies with real science and real potential.